Pharmacokinetic and in vivo efficacy studies of the mycobactin biosynthesis inhibitor salicyl-AMS in mice Journal Article

   

Authors:	Lun, S.; Guo, H.; Adamson, J.; Cisar, J. S.; Davis, T. D.; Chavadi, S. S.; Warren, J. D.; Quadri, L. E. N.; Tan, D. S.; Bishai, W. R.
Article Title:	Pharmacokinetic and in vivo efficacy studies of the mycobactin biosynthesis inhibitor salicyl-AMS in mice
Abstract:	Mycobactin biosynthesis in Mycobacterium tuberculosis facilitates iron acquisition, which is required for growth and virulence. The mycobactin biosynthesis inhibitor salicyl-AMS [5=-O-(N-salicylsulfamoyl)adenosine] inhibitsM. tuberculosis growth in vitro under iron-limited conditions. Here, we conducted a single-dose pharmacokinetic study and a monotherapy study of salicyl- AMS with mice. Intraperitoneal injection yielded much better pharmacokinetic parameter values than oral administration did. Monotherapy of salicyl-AMS at 5.6 or 16.7 mg/kg significantly inhibitedM. tuberculosis growth in the mouse lung, providing the first in vivo proof of concept for this novel antibacterial strategy. Copyright © 2013, American Society for Microbiology. All Rights Reserved.
Journal Title:	Antimicrobial Agents and Chemotherapy
Volume:	57
Issue:	10
ISSN:	0066-4804
Publisher:	American Society for Microbiology
Date Published:	2013-10-01
Start Page:	5138
End Page:	5140
Language:	English
DOI:	10.1128/aac.00918-13
PROVIDER:	scopus
PUBMED:	23856770
PMCID:	PMC3811451
DOI/URL:	http://www.scopus.com/inward/record.url?eid=2-s2.0-84884225510&partnerID=40&md5=f5dba5c74da8472a9ee29378f8cd5a2c
Notes:	--- - "Export Date: 1 October 2013" - "CODEN: AMACC" - "Source: Scopus"

https://synapse.mskcc.org/synapse/works/has_related_data_chk/46068